Detection of Chlamydia trachomatis in genital swabs:comparison of commercial and in house amplification methods with culture by Shattock, R M et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detection of Chlamydia trachomatis in genital swabs
Citation for published version:
Shattock, RM, Patrizio, C, Simmonds, P & Sutherland, S 1998, 'Detection of Chlamydia trachomatis in
genital swabs: comparison of commercial and in house amplification methods with culture' Sexually
transmitted infections, vol 74, no. 4, pp. 289-93., 10.1136/sti.74.4.289
Digital Object Identifier (DOI):
10.1136/sti.74.4.289
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher final version (usually the publisher pdf)
Published In:
Sexually transmitted infections
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
Original
article
Detection of Chlamydia trachomatis in genital
swabs: comparison of commercial and in house
amplification methods with culture
Richard M Shattock, Craig Patrizio, Peter Simmonds, Sheena Sutherland
Aims: To evaluate the sensitivity of the Roche Cobas, Roche Amplicor plate kit, ligase chain
reaction (LCR), and an in house polymerase chain reaction (PCR) by titration of purified
elementary bodies (EB) and also to test 245 urethral and endocervical specimens for Chlamydia
trachomatis by the four assays as well as conventional culture.
Study design: EB titrations were run in duplicate in each commercial assay and six times in the
in house PCR. Clinical samples were aliquoted and tested by each assay and were considered
positive if C trachomatis was detected by two or more separate tests or if the sample was either
culture or immunofluorescence positive.Major outer membrane protein (MOMP) specific prim-
ers were used as a confirmatory assay for the in house PCR.
Results: The in house PCR, Roche Cobas Amplicor, LCR, and Amplicor plate kit gave detec-
tion limits of approximately 1, 1–2, 2, and 2–4 EBs respectively. By the criteria described above
for definition of a C trachomatis positive result in clinical samples we identified 23 true positives
among the 245 clinical specimens. The in house PCR detected all 23 giving a sensitivity of 100%
and a specificity of 98%. The Roche Cobas Amplicor, Roche Amplicor plate kit, and LCR
detected 21, 19, and 19 of these respectively giving sensitivities of 87.5%, 82%, and 82% respec-
tively and specificities of 99.5%, 99%, and 100% respectively. The culture gave a sensitivity of
78% and specificity of 100%.
Conclusion: All four amplification assays had a greater sensitivity than the culture used routinely
in this laboratory. The in house plasmid PCR had the greatest sensitivity and when combined
with confirmation by immunofluorescence detected the greatest number of positives. This
increased sensitivity is likely to have been achieved by the use of a DNA purification step and of
nested primers in the amplification stage and their combined use in routine diagnostic assays for
chlamydia might increase the frequency of C trachomatis detections. However, this assay is much
less user friendly than the two semiautomated commercial assays investigated in this study.
(Sex Transm Inf 1998;74:289–293)
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Introduction
Chlamydia trachomatis serovars D-K are the
commonest cause of non-gonococcal urethritis
in males and mucopurulent cervicitis and ure-
thritis in females. Many patients are asympto-
matic and if untreated they will be a risk both to
their partners and to themselves. For example
ascending infection can occur, and in females
can result in pelvic inflammatory disease (PID)
causing ectopic pregnancies and infertility. It is
therefore desirable to identify chlamydial
infections in infected individuals and adminis-
ter appropriate treatment before further com-
plications arise.
Laboratory diagnosis of C trachomatis was
originally based on the culture of urethral and
endocervical swabs.1 More recently, attempts
have been made to develop more rapid
methods, such as the detection of chlamydial
antigen by immunological assays. Among
these, direct fluorescent antibody assays (DFA)
and enzyme linked immunosorbent assays
(ELISA) using monoclonal antibodies directed
against chlamydial antigens have become
widely used. These show sensitivities similar to
that of culture, although precise comparisons
are influenced by the methods of sample
collection, transport, and storage.2 3
Alternatives to immunological detection are
methods based upon the amplification of bacte-
rial nucleic acid sequences.4 Two techniques
developed for the detection of C trachomatis are
the ligase chain reaction (LCR, Abbott)5 6 and
Roche Cobas Amplicor. Both methods amplify
sequences from a cryptic plasmid present within
bacterial cells at copy numbers of 7–10.7 These
methods may therefore be more sensitive than
amplification of single gene sequences from the
bacterial genome such as those coding for the
major outer membrane protein (MOMP). The
Roche Cobas Amplicor is an automated system
of the conventional Roche Amplicor polymerase
chain reaction (PCR) plate kit. Like the LCR,
the Roche Cobas has a manual sample process-
ing but allows automated amplification and
detection as well as result reporting.
Our study involved the comparison of Roche
Cobas Amplicor, Roche Amplicor plate kit,
Abbott LCR, in house PCR, and culture on
swabs collected routinely over 2 weeks from
245 patients attending a single genitourinary
medicine clinic (GUM) (221) and a single
local general practice (24).
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Materials and methods
STUDY POPULATION
The specimens used in the study were consecu-
tive swabs sent in sucrose phosphate (2SP)
transport medium for routine culture (251) over
10 working days with the exception of six
samples. Three of the excluded samples were
conjunctival swabs, one was a rectal swab, and
two had insuYcient 2SP for all the tests to be
performed. The remaining 245 were collected
from 120males and 125 females.Urethral swabs
numbered 123 (120 male, three female), en-
docervical swabs 121, and one female swab was
site unknown. The GUM patients comprised
138 patients attending for the first time, 66 pre-
vious attenders with a new episode of illness, and
20 previous attenders returning for follow up of
a recent episode. None of the general
practitioner patients was on follow up visits.
COLLECTION OF SAMPLES
To avoid the swab sample variation that can
occur when multiple swabs are taken, only one
swab was submitted for each patient. The swab
sent for chlamydia culture was the second swab
taken, the first swab being sent for bacteriology.
The volume of 2SP was not increased so that
our routine culture sensitivity would not be
compromised and to ensure that our service to
the patients remained as normal. The swabs
were received in approximately 1.2 ml of 2SP
transport medium. Specimens were vortexed
for 1 minute, 500 µl of the specimen was
cultured, and four aliquots of 100 µl were used
for each of the other tests. The remaining
specimen (approximately 300 µl) was stored for
immunofluorescence (IF) if required.
The LCR (Abbott) required resuspension of
the sample in manufacturer’s diluent as 2SP is
unsuitable for this test. Aliquots tested by this
method were prepared according to the manu-
facturer’s instructions for testing urine samples
and so were centrifuged at 15 000 rpm for 10
minutes, the supernatant discarded, and pellets
stored at −70°C. Pellets were resuspended in
100 µl of the manufacturer’s urine resuspen-
sion buVer before testing.
ELEMENTARY BODY TITRATIONS
Elementary bodies (EBs) were purified and
dilutions made in phosphate buVered saline
(PBS). Dilutions containing 1000, 100, 10, 4,
2, 1, and 0.1 EBs in 100 µl were run in dupli-
cate on each assay except the in house PCR
which was repeated six times. The detection
limit was calculated by taking the dilution fac-
tor into account during sample processing and
assuming 10 plasmid copies per EB. All assays
used 100 µl volumes. DNA for the in house
PCR was eluted in 50 µl of which 5 µl was used
in the PCR (1/10).The RocheCobas and Roche
Amplicor plate kit used 50 µl of prepared sample
from a total volume of 400 µl (1/8). The LCx
used all of the 100 µl in the amplification
CHLAMYDIA CULTURE
Volumes of 500 µl of each sample were
inoculated with centrifugation at 37°C for 1
hour onto monolayers of McCoy cells in the
presence of cycloheximide and incubated for 72
hours at 37°C. Cells were stained with iodine
and inspected microscopically for the presence
of glycogen containing inclusions.8 9
IMMUNOFLUORESCENCE
Slides were prepared by cytospin method using
150 µl of sample and fixed in methanol.
PathoDX MOMP specific antibody was used
for EB detection.
IN HOUSE PCR
DNA was extracted using the Qiamp viral
RNA extraction kit. Nested primers (table 1)
were used to amplify a 108 bp fragment of the
cryptic plasmid. The amplicon was detected by
ethidium bromide staining after electrophore-
sis through a 2% agarose gel. A second assay
using nested primers to amplify a 94 bp
fragment of the MOMP gene (table 1) was
performed on all samples which gave a positive
reaction with the plasmid assay.
ROCHE AMPLICOR PLATE KIT AND ROCHE COBAS
AMPLICOR
All Roche assays were carried out according to
the manufacturer’s instructions. During the
study Roche changed the sample preparation
method for the plate kit so that the newer kit
was used for the EB dilution series and the
older kit for the 245 specimens.
ABBOTT LIGASE CHAIN REACTION
Pelleted samples, resuspended in LCx urine
resuspension buVer, were tested according to
the manufacturer’s instructions.
DEFINITION OF A POSITIVE SAMPLE
All 245 clinical samples were tested by culture,
in house PCR, and Roche Cobas Amplicor,
Roche Amplicor plate kit, and Abbott LCR.
Immunofluorescence was carried out on dis-
crepant results as a confirmatory test and all
plasmid positive samples were retested with
MOMP primers. Samples were considered
positive if (1) culture positive, (2) culture
negative but positive by IF, or (3) positive in
two or more of any other assays.
Results
By the criteria defined in the methods section a
total of 23 of the 245 (9.4%) clinical specimens
were positive for C trachomatis. Eleven (9%)
were male samples and 12 (9.5%) were female
samples.
CLINICAL FEATURES
Patients could be classified as asymptomatic,
symptomatic possibly chlamydia related (SPC),
and symptomatic but unrelated to chlamydia
Table 1 In house PCR primer sequences
Region Primer Sequence 5'-3'
Plasmid Outer sense CTTTGCGCACAGACGATCTA
Outer antisense CAAATACTCTCCCATTTCTCC
Inner sense GCATCCAATCAATCAGATTTCC
Inner antisense GTGTATTTTTGCAACTCCTCC
MOMP Outer sense GAAAAAACTCTTRAARTCGG
Outer antisense CGNANGCTWATRGCRTCRCACCAAG
Inner sense TGCCTGTRGGGAAYCCWKCTGAWCCAAG
Inner antisense CAAGTNCNRCAAGGATCRCAAGGATC
Ambiguities: N = A,T,G,C; W = A/T; R = A/G; K = G/T; Y = C/T.
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(UC). There were 104 asymptomatic patients of
whom 11 had returned for test of cure investiga-
tions and five were known contacts of chlamydia
positive partners. Eighty three patients had
symptoms unrelated to chlamydia and 58 had
symptoms possibly related to chlamydia. The
positivity rate in the three categories was (a)
10%, (b) 2.4%, and (c) 19%. Of the 30 patients
with NSGI, nine (30%) were positive and two of
the 27 (7.4%) with vaginal discharge; one of
these also had genital warts. Ten (10%) of the
asymptomatics were positive; two of these were
tests of cure—one male, one female—and two
were female contacts of known positives. The
other asymptomatic patients were one male and
five females. The remaining two positives were
detected in two female patients with other
STDs—one with herpes simplex infection the
other with genital warts.
ASSAY RESULTS
Using the Roche Cobas Amplicor, 22 samples
were positive, one of which was repeat Cobas
positive but IF negative (table 2 , case 5: inde-
terminate). The Roche plate kit detected 21
positives, 18 of which were culture positive
while two of the remaining three samples were
negative on repeat testing (table 2, cases 6 and
7). The other Roche positive was LCR positive
and in house PCR positive but IF negative.
There were also two Roche equivocals, one was
negative on repeat testing and the second
repeated equivocal (table 2, case 12).
The LCR detected 19 positives and one
equivocal which was IF negative but Cobas and
in house PCR positive (table 2, case 12). There
were no LCR false positives.
In house PCR gave a total of 27 positives
using the plasmid primers. There were three
presumed false positives which were negative
by PCR using MOMP primers and negative
upon repeat testing by the plasmid primers
(table 2, cases 2, 3, and 4). One specimen was
repeatedly positive using plasmid primers,
MOMP assay negative and IF negative (table
2, case 1: indeterminate). By the criteria for
positivity described above, these samples have
been scored as false positives, although the lat-
ter sample may contain chlamydial DNA at a
low level. Two specimens were repeatedly posi-
tive by plasmid primers, negative by MOMP
primers, but positive by IF (cases 8 and 9).
There was also one specimen positive by plas-
mid primers, culture positive, and IF positive
with four EBs but was negative by all other
methods (case 10). Table 3 compares sensitiv-
ity and specificity of resolved results in all the
assays, with in house PCR results given before
and after confirmation with the MOMP prim-
ers. Retesting with MOMP primers failed to
detect three positives which were confirmed by
IF. Confirmation of plasmid positive screens by
MOMP primers would lower the sensitivity to
86% but would increase specificity to 100%.
Assuming all non-discrepant positives would
have been IF positive, confirmation by IF
would give a sensitivity of 95.6%.
Table 3 Comparison of methods with confirmed results on sensitivity and specificity
Test and result
Confirmed results
Positive Negative Sensitivity (%) Specificity (%)
Plasmid PCR only*
positive 23 4 100 98
negative 0 218
Plasmid and MOMP PCR†
positive 20 0 86 100
negative 3 222
Roche Cobas
positive 21 1 87.5 99.5
negative 2 221
Roche plate kit
positive 19 2 82 99
negative 4 220
LCR
positive 19 0 82 100
negative 4 222
Culture
positive 18 0 78 100
negative 5 222
*Sensitivities and specificities calculated if plasmid results only are taken.
†All positives with plasmid primers were retested using MOMP primers. A negative by MOMP
primers was considered a false plasmid positive. IF results were not taken into account.
Table 2 (A) Presumed false positives
ID Sex Spec Type Diag/Hist PPCR1 MPCR2 Culture LCR Cobas Roche IF Conclusion
1 M3 U4 ASYM5 (+/+)6 − − − − − − Ind15
2 M U ASYM (+/−) − − − − − − IHP7 false+
3 F8 EC9 rash (+/−) − − − − − − ”
4 F EC warts (+/−) − − − − − − ”
5 M U TOC10 − − − − (+/+) − − Ind
6 M U TOC − − − − − (+/−) − Roche false+
7 F EC V.DIS11 − − − − − (+/−) − ”
(B) Presumed false negatives
ID Sex Spec Type Diag/Hist PPCR MPCR Culture LCR Cobas Roche IF Conclusion
8 M U ASYM/Partner NSGI12 (+/+) − − − + − 2EBs Low level+
9 M U TOC (+/+) − − − − − 3EBs ”
10 F EC V.DIS (+/+) − + − − − 4EBs ”
11 M U NSGI + + − + + + 6EBs
12 F EC ASYM (+/+) − − (eq)13 + (eq/eq) − Low level+
1 Plasmid PCR; 2 MOMP PCR; 3 Male; 4 Urethral; 5 Asymptomatic; 6 ( ) indicates results of screening and repeat assays; 7 In house PCR; 8 Female; 9 Endocervical; 10
Test of cure; 11 Vaginal discharge; 12 Partner with non-specific urethritis; 13 Indicates an equivocal result; 15 Indeterminate.
Table 4 Elementary body titrations for the three
commercial assays and the in house PCR. 6/6 indicates six
positive out of six tests performed
Tests
Number of EBs present/100 µl
1000 100 10 4 2 1 0.1
In house PCR
(Plasmid) 6/6 6/6 6/6 6/6 6/6 6/6 1/6
In house PCR
(MOMP) 2/2 2/2 2/2 0/2 0/2 0/2 0/2
Roche Cobas 2/2 2/2 2/2 2/2 2/2 1/2 0/2
Roche plate kit 2/2 2/2 2/2 2/2 1/2 0/2 0/2
LCR 2/2 2/2 2/2 2/2 2/2 0/2 0/2
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Comparing the confirmed results for the
diVerent assays (table 3) revealed that the in
house PCR gave the best sensitivity without
MOMP primers, while LCR, culture, and in
house PCR (with MOMP primers) all gave
100% specificity. Figure 1 shows the ratio of the
sample reading/cut oV and outlines a clear
distinction between positives and negatives par-
ticularly for the Roche Cobas, compared with
the earlier Roche plate kit which had ratios close
to the cut oV and the LCx which show a number
of samples with equivocal readings. A lowering
of the LCx cut oV may increase the detection
rate and certainly would have in this case.
Discussion
A number of previous studies have compared
various commercial assays, culture systems, in
house PCRs, and IF for C trachomatis,10–12
although few have evaluated more than two
assays using a common set of specimens. This
study was designed to carry out a comprehen-
sive analysis of currently available diagnostic
assays and used a variety of criteria to define
positive samples in the calculation of the sensi-
tivity and specificity of each. The study also
included an EB dilution series which was har-
vested at 72 hours to ensure inclusions had
released EBs and reticulate bodies had reor-
ganised into EBs. No reticulate bodies were
seen during total EB counts.
The results given in table 4 for the plasmid
based assays may show diVerences that were
simply due to chance since in the very dilute
samples the EB distribution would be deter-
mined according to the Poisson distribution.
This diYculty could have been partially
overcome if, for example, 25 replicates of each
dilution had been tested in each assay but such
an exercise was well beyond our budget. How-
ever, it is also possible that the diVerences may
be greater than shown. If the volumes used in
each assay are allowed for in the calculation
and plasmid numbers rather than EBs are used
the true endpoints may be 1, 1–2, 2–3, and 20
plasmid copies for the in house PCR, Roche
Cobas Amplicor, Roche Amplicor plate kit
(improved version), and LCR respectively.
A number of discrepant results were ob-
served in this study. Initial in house PCR
screening with plasmid primers gave 27
positive results, 23 of which were confirmed
positive. Three unrepeatable positives with the
plasmid primers were probably due to con-
tamination during the PCR in spite of strict
adherence to the rules for PCR performance. A
sample from one asymptomatic patient who
was repeatedly positive by the plasmid primers
may have contained chlamydial DNA, but
unfortunately no follow up sample was avail-
able to confirm this.
A number of workers have shown that
patients can be PCR positive, even 4 weeks
after treatment,13 while experimental work in
monkeys has shown that PCR can detect
chlamydia up to 5 weeks after samples become
culture negative.14 In this study 10 specimens
were from patients who had been diagnosed as
positive and had returned for a check following
treatment; two of these were positive; one by all
assays and one by in house PCR and IF.
The Roche Cobas Amplicor gave positive
results for 21 samples compared with 19 on the
Roche plate kit. Since the clinical samples
reported here were tested Roche have modified
their plate kit. The modified version, used in
the dilution series, appears to be closer in sen-
sitivity to the Cobas.
The LCR gave no false positive results but
failed to detect one sample positive by culture
and two samples positive by in house PCR and
IF. An additional sample which was in house
PCR and Roche Cobas positive gave an LCR
result just below the cut oV. These false
negatives could not be explained by an absence
of the 7.5 kb cryptic plasmid in that the in house
PCR primers used this target sequence for
amplification. It is possible that a mutation
could have prevented hybridisation of the probes
to the target sequence, or LCR inhibitors may
have been present.The presence of inhibitors for
urines has been discussed previously for LCR in
which prolonged storage and freeze thawing
reduced the eVects of these inhibitors.15 Since
two of these missed positives were male urethral
swabs the possibility of inhibitors being present
cannot be ruled out. However, a more likely
explanation was that the number of elementary
bodies was very low in these specimens. The
culture system used 500 µl of specimen yet
frequently detected extremely low numbers of
inclusions in the culture. Smaller aliquots may
not have contained any or very few elementary
bodies even though before aliquoting, samples
were vortexed for 1minute to ensure homogene-
ous mixing. Low levels of plasmid DNA may be
detected more eYciently by nested PCR, which
increases theoretical sensitivities for single cop-
ies of target sequence.16
Previous work has suggested that the sensi-
tivities of Roche PCR plate kit and Abbott
LCR are equivalent and that the cut oV level of
both assays is 2–4 elementary bodies,17 perhaps
Figure 1 Comparison of sample reading/cut oV ratios between commercial assays for 245
clinical specimens. Cut oV = 1.00;l = positive;¥ = negative;[ = false positive;s=
indeterminate.
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explaining their inability to detect a culture
positive sample with a low level of elementary
bodies detected by IF. In automating the
system Roche have been able to increase sensi-
tivity and specificity of their assay.
The in house PCR was 9% more sensitive
than the Roche amplification system with a
small loss in specificity (98%). Processing time
was reduced using Qiamp viral RNA extraction
columns with a vacuum manifold. This in-
creased sample throughput considerably when
compared with conventional phenol/chloroform
extraction methods. The extraction method
allows the processing of 48 samples within an
hour and positive results could be confirmed
within 48 hours. If the in house PCR was used
for routine diagnosis, all plasmid positives would
be confirmed with MOMP and/or IF before
reporting to the clinician. The plasmid primers
were more sensitive than the MOMP primers as
shown by the two plasmid/IF positive but
MOMP primer negative samples. One sample
was repeatedly plasmid positive butMOMP and
IF negative which might indicate that some
samples may be unconfirmable; these would
have to be reported as indeterminate and a
repeat sample supplied.
The semiautomated commercial assays had
distinct advantages over the in house PCR
from the technician’s point of view in that the
preparation step before amplification was
much simpler and the hands on time thereafter
was much less.When large numbers of samples
have to be processed every day the risk of
operator error increases and this risk was
greatest with the in house assay. A speedier
result was the other main advantage of the
commercial assays. The advantages of the in
house assay in addition to greater sensitivity
were cost and the fact that the result would be
confirmed before reporting. However the
royalty payment to Roche would decrease cost
savings advantages.
The demonstrated lower sensitivity of cul-
ture means that it can no longer be regarded as
the gold standard forC trachomatis. In addition,
variations in sensitivity from centre to centre,
the need for well taken specimens transported
rapidly in cold conditions, and its unsatisfac-
tory detection rate in urines all make it more
fallible than molecular methods. The addi-
tional positives detected by in house PCR
increased the detection rate from 8% (as previ-
ously reported in this laboratory)12 to 9.5%.
These increased detection rates are also seen
with the commercial assays. An expanded gold
standard should include the use of nucleic acid
amplification technologies, either in house
PCRs or commercially available tests, because
of their higher sensitivities.
We would like to thank Azra Sharif-Qayyum for expert techni-
cal assistance in the routine culture, Roche Diagnostics for the
supply of Amplicor PCR kits and Abbott for the use of the LCx
system.
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